Literature DB >> 12128089

Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases.

Javier Díaz-Nido1, Francisco Wandosell, Jesús Avila.   

Abstract

Protein aggregation into dense filamentous inclusions is a characteristic feature of many etiologically diverse neurodegenerative disorders including Alzheimer's disease (AD), spongiform encephalopathies, and tauopathies. Thus, beta-amyloid peptide (Abeta) accumulates within senile amyloid plaques in AD, protease-resistant prion protein constitutes the amyloid deposits in spongiform encephalopathies and tau protein gives rise to neurofibrillary tangles (NFT) both in AD and in tauopathies. Curiously, these abnormal protein inclusions contain, in addition to their major peptide components, some associated sulfated glycosaminoglycans (sGAG). Here we discuss the proposal that the binding of sGAG to aggregate-forming peptides may modify the pathogenic process depending on their subcellular localization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12128089     DOI: 10.1016/s0196-9781(02)00068-2

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  30 in total

1.  Learning from Synthetic Models of Extracellular Matrix; Differential Binding of Wild Type and Amyloidogenic Human Apolipoprotein A-I to Hydrogels Formed from Molecules Having Charges Similar to Those Found in Natural GAGs.

Authors:  Silvana A Rosú; Leandro Toledo; Bruno F Urbano; Susana A Sanchez; Graciela C Calabrese; M Alejandra Tricerri
Journal:  Protein J       Date:  2017-08       Impact factor: 2.371

Review 2.  Molecular interactions of amyloid nanofibrils with biological aggregation modifiers: implications for cytotoxicity mechanisms and biomaterial design.

Authors:  Durga Dharmadana; Nicholas P Reynolds; Charlotte E Conn; Céline Valéry
Journal:  Interface Focus       Date:  2017-06-16       Impact factor: 3.906

Review 3.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

Review 4.  On the key role played by altered protein conformation in Parkinson's disease.

Authors:  L F Agnati; E Baldelli; N Andreoli; A S Woods; V Vellani; D Marcellino; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

5.  Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein.

Authors:  L F Agnati; G Leo; S Genedani; L Piron; A Rivera; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-11-19       Impact factor: 3.575

Review 6.  Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution.

Authors:  Massimo Stefani; Christopher M Dobson
Journal:  J Mol Med (Berl)       Date:  2003-08-27       Impact factor: 4.599

7.  Glycosaminoglycans have variable effects on α-synuclein aggregation and differentially affect the activities of the resulting amyloid fibrils.

Authors:  Surabhi Mehra; Dhiman Ghosh; Rakesh Kumar; Mrityunjoy Mondal; Laxmikant G Gadhe; Subhadeep Das; Arunagiri Anoop; Narendra N Jha; Reeba S Jacob; Debdeep Chatterjee; Soumik Ray; Nitu Singh; Ashutosh Kumar; Samir K Maji
Journal:  J Biol Chem       Date:  2018-06-29       Impact factor: 5.157

8.  Heparin-induced circular dichroism of chloroquine.

Authors:  F E Stanley; A M Warner; S M Gutierrez; A M Stalcup
Journal:  Biochem Biophys Res Commun       Date:  2009-07-24       Impact factor: 3.575

Review 9.  Lessons learned from protein aggregation: toward technological and biomedical applications.

Authors:  César L Avila; Silvina Chaves; Sergio B Socias; Esteban Vera-Pingitore; Florencia González-Lizárraga; Cecilia Vera; Diego Ploper; Rosana Chehín
Journal:  Biophys Rev       Date:  2017-09-13

10.  Glypican-1 mediates both prion protein lipid raft association and disease isoform formation.

Authors:  David R Taylor; Isobel J Whitehouse; Nigel M Hooper
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.